A Study on Eradication Rate of Triple Therapy Including Low Dose-PPI, Clarithromycin, Amoxicillin According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Amoxicillin (Primary) ; Clarithromycin (Primary) ; Ilaprazole (Primary)
Indications Helicobacter pylori infections
Focus Therapeutic Use
Sponsors Il-Yang

18 Sep 2020 Results published in the Medicine
18 Sep 2020 Status changed from recruiting to completed, as per Results published in the Medicine
07 Apr 2017 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com